Document:

Particiaption Agreement

 Exhibit 10.11 
 PARTICIPATION AGREEMENT 
 This Participation Agreement
(this “Agreement”) is entered into as of the 28th day of March 2008 (the “Effective Date”) by and between BG Medicine, Inc., a corporation having offices at 610 N. Lincoln Street, Waltham, Massachusetts 02451 (“BGM”)
and Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064-3500, USA (“Participant”; each of Participant and BGM are sometimes referred to individually as a “Party” and collectively as the “Parties”).

 WHEREAS, BGM and leading healthcare companies, including Merck, AstraZeneca and Philips, intend to collectively design and
conduct a number of activities (the “HRP Initiative”) in order to advance the understanding, recognition and management of High Risk Plaque for the benefit of all stakeholders in the healthcare system as described in the form of Program
Outline to be attached hereto as Exhibit A-1 (the “HRP Program, as further defined below”); and 
 WHEREAS, BGM
will administer, coordinate and implement the HRP Program; and 
 WHEREAS, Participant desires to sponsor the HRP Initiative and
to obtain access to the Data (as defined below) generated in the performance of the HRP Initiative, and a non-exclusive license under certain intellectual property rights, as set forth herein. 
 NOW, THEREFORE, in consideration of the foregoing, and other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows. 
 1. Definitions. Capitalized terms
used herein shall have the definition provided in the introductory paragraph or recitals above, or the definition provided below, as applicable. 
 “Affiliate” means any corporation, firm, partnership or other entity which directly or indirectly controls or is controlled by or is under common control with a Party. For purposes of
this definition, “control” means ownership, directly or through one or more Affiliates, of (a) fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors, in the case of a corporation,
(b) fifty percent (50%) or more of the equity interests in the case of any other type of legal entity, status as a general partner in any partnership, or (c) any other arrangement whereby a Party controls or has the right to control
the Board of Directors or equivalent governing body of a corporation or other entity. 
 “Applicable Law” means
all applicable common law, laws, constitutional provisions, ordinances, statutes, rules, regulations, administrative rulings, executive orders and other pronouncements having the effect of law of any federal, national, multinational, state,
provincial, county, city or other political subdivision, agency or other body, domestic or foreign, including but not limited to any applicable rules, regulations, guidelines, or other requirements of governmental agencies that may be in effect from
time to time. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 “Confidential Information” means confidential scientific, business, or
financial information provided by one Party or other sponsor of the HRP Initiative (a “disclosing Party”) to any other Party or other sponsor of the HRP Initiative (a “receiving Party”) pursuant to this Agreement; provided, that,
Confidential Information does not include: 
 (a) information that is or becomes publicly known or that is or becomes available
from public sources; 
 (b) information that is already known by the receiving Party, or information that is independently
created or compiled by the receiving Party without reference to or use of the provided information; or 
 (c) information that
relates to potential hazards or cautionary warnings associated with the production, handling, or use of the subject matter of the HRP Program; or 
 (d) information that is provided to the receiving Party by a third party who is not bound by obligations of confidentiality to the disclosing Party. 
 “Data” means all data first produced in the performance of the HRP Initiative as described in the HRP Program that has been
anonymized so as to be outside the scope of international data protection laws generally, as well as, deidentified in accordance with the requirements of the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule, the regulations
promulgated thereunder and Applicable Law. 
 “Participant Proprietary Product” means any drug compound or
medical device controlled by Participant. For purposes of this definition, “control” means the possession by Participant of (a) a 50% or more ownership interest in a drug compound or medical device or (b) a licensing interest
that permits Participant to exclusively develop, manufacture and sell such drug compound or medical device in some or all indications, uses and countries. 
 “Project Invention” shall have the definition provided in Section 5.2. 
 “Reports” shall have the definition provided in Section 4. 
 “HRP Program” means a written plan describing the activities to be carried out in support of the HRP Initiative; as such written plan may be amended, modified or updated. Each HRP Program shall include the resource
requirements of, and budget applicable to, the conduct of each HRP Program. The initial HRP Program shall be developed by the SPB and approved by the JSC prior to sixty (60) days after the Effective Date and attached hereto as Exhibit
A-1 and each additional HRP Program shall be developed by the SPB and approved by the JSC prior to the initiation of any Program Activities with respect to each such HRP Program and attached hereto as addendums to Exhibit A. 

“Program Activity” means the activities conducted as part of the HRP Initiative as described in the applicable HRP
Program. 
 “Scientific Program Board” or “SPB” means the scientific advisory board comprised
of academic experts in applicable fields, representatives of BGM, Participant, and other sponsors of the HRP Initiative that are approved by the JSC, as further described in Section 3.2. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 “Joint Steering Committee” or the “JSC” means the joint
steering committee comprised of those representatives of BGM, Participant, and other sponsors of the HRP Initiative, as further described in Section 3.1. 
 “Third Party Contractor” means any third party contract research organization, research laboratory or similar entity engaged by Participant to perform development services with respect to
any Participant Proprietary Product. 
 2. HRP Initiative. 
 2.1 Performance of HRP Initiative. BGM shall coordinate, administer and execute the HRP Initiative as provided in the HRP Program. The
HRP Initiative shall be implemented through the conduct by BGM of Program Activities, each of which will be described in the HRP Program and/or in amendments thereto. 
 2.2 HRP Program; Amendments. Within sixty (60) days of the Effective Date the initial HRP Program shall be prepared by the SPB, approved by the JSC and attached hereto as Exhibit A-1.
Any changes to the HRP Program shall be prepared by the SPB and approved by the JSC in accordance with Section 3.1 below. 
 2.3 Additional Participants. Excluding BGM, the HRP Initiative shall have no less than two (2) sponsors (including Participant). BGM will actively recruit additional participants (“Subsequent Participants”) until a
total of five (5) Participants have executed participation agreements. To join the HRP Initiative, Subsequent Participants shall execute participation agreements including the same terms set forth in this Agreement. Subsequent Participants must
execute participation agreements joining the HRP Initiative prior to 12/31/2007; Thereafter, Subsequent Participants shall only be permitted to join the HRP Initiative with the consent of at least two-thirds of the JSC. Any terms of a Subsequent
Participant’s agreement materially different from this Agreement shall be approved in writing by the JSC, in addition to any approval process by which BGM is obligated, such approval not to be unreasonably withheld. 
 2.4 Open Technology. In order to promote widespread availability and adoption of imaging technology inventions arising from the HRP
Initiative that are specific to imaging technology equipment, and their applications to various types of imaging equipment, these imaging technology equipment inventions and applications resulting from use of the Project Inventions shall be made
available under customary multi-vendor terms and polices to GE, Philips, and Siemens and any other established manufacturer of proprietary imaging equipment who possesses the appropriate level of know-how and experience to implement new technology
arising from the HRP Initiative. 
 3. Governance 
  

	 	3.1	Joint Steering Committee. 

 (a) Formation; Responsibilities. As soon as practicable after the Effective Date, the Joint Steering Committee shall be formed to (i) oversee the overall conduct and progress of the HRP Initiative; (ii) establish such
additional committees as may be necessary to achieve the objectives of the HRP Initiative and, to the extent so established, approve the governing

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
procedures applicable thereto; (iii) finalize and approve each Program Activity (including all budgets and work plans included therein) and/or each amendment to any HRP Program proposed by
the SPB; (iv) make all decisions with respect to the initiation and performance of any Program Activity and the application of funds to such Program Activity; (v) approve all press releases related to the HRP Initiative; (vi) review
and approve all patent filings to be made covering any Project Inventions; (vii) provide a forum for the resolution of disputes among the Parties with respect to the HRP Initiative; (viii) negotiate, and if desirable, grant
commercialization rights to the Data and Project Inventions; (ix) if necessary, dissolve the SPB; and (x) approve, and if necessary, replace or discharge the Co-Chairs of the SPB. 
 (b) Designation of Representatives. BGM and each Participant shall have the right to designate one (1) member to serve on the
JSC. Participant shall provide written notice to BGM of the name of such member promptly after the Effective Date. Unless otherwise agreed by the Parties, (i) the Co-chairs of the SPB shall be non-voting members of the JSC; (ii) the
representative of BGM on the JSC shall be the Chairs of the JSC and (iii) the representative of BGM on the JSC shall serve as Secretary to the JSC. Each Party shall have the right at any time to substitute individuals, on a permanent or
temporary basis, for any of its previously designated representatives to the JSC by giving written notice to the other Party. 
 (c) Meetings. The JSC shall establish a schedule of times for regular meetings, taking into account, without limitation, the planning needs of the HRP Initiative and the responsibilities of the JSC. The Secretary shall have the
responsibility for preparing and circulating to each JSC member an agenda for each JSC meeting not later than one (1) week prior to such meeting. The JSC shall meet not less than once per calendar quarter or at such other intervals, as it deems
appropriate. The Secretary shall give all members of the JSC proper and timely notice of any meeting to be held. Meetings of the JSC may be held in person or by teleconference or videoconference. Upon prior request by any member of the JSC, any JSC
meeting may be conducted excluding the Co-chairs of the SPB. 
 (d) Quorum. At each JSC meeting, (i) the presence of
at least a majority of the JSC members shall constitute a quorum and (ii) each member who is present shall have one vote on all matters before the JSC at such meeting. All decisions of the JSC shall be made by vote or written consent of the
majority of all members. In the event that the JSC is unable to resolve any matter before it for consideration, such matter shall be resolved in accordance with Section 3.1(f). 
 (e) Minutes; Updates. The JSC shall keep minutes of its meetings that record all decisions and all actions recommended or taken in
reasonable detail. Drafts of the minutes of each meeting, as well as an update on the status of all Program Activities, shall be prepared and circulated to the members of the JSC by the Secretary within a reasonable time, not to exceed ten
(10) business days, after the meeting. Each member of the JSC shall have the opportunity to provide comments on the draft minutes. Draft minutes shall be approved or disapproved (and, in case of the latter, revised) as soon as practicable. Upon
approval, final minutes of each meeting shall be circulated to the members of the JSC by the Secretary. 
 (f) Dispute
Resolution. The JSC members shall use reasonable efforts to reach agreement on any and all matters presented to it. In the event that, despite such reasonable

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
efforts, the agreement on a particular matter cannot be reached by the JSC in accordance with Section 3.1(d) within ten (10) days after the JSC first meets to consider such matter (each
such matter, a “Disputed Matter”), then the JSC shall abandon consideration of the Disputed Matter and the subject matter of the Disputed Matter shall not be implemented. 
  

	 	3.2	Scientific Program Board. 

 (a) Formation; Responsibilities. As soon as practicable after the Effective Date, the Scientific Program Board shall be formed to (i) provide advice on the direction and performance of the Program Activities that make up the HRP
Initiative; (ii) propose and design Program Activities for submission to and the approval of the JSC; (iii) propose such additional scientific subcommittees as may be necessary to achieve the objectives of any Program Activity for
submission to and the approval of the JSC; (iv) identify any public disclosure needs related to the HRP Initiative and develop scientific disclosure and publication materials for approval by the JSC; and (v) review and present to the JSC
all Project Inventions. The SPB shall use reasonable efforts to reach agreement on any and all matters; provided that, in the event that the SPB is unable to resolve any matter before it, such matter shall be referred to the JSC for resolution. BGM
shall give good faith consideration to the advice of the SPB with respect to the conduct of all Program Activities; provided, that BGM shall at all times adhere to the requirements of the HRP Program in the performance of the HRP Initiative.

 (b) Designation of Representatives. The JSC shall appoint the Co-Chairs and Secretary of the SPB, which shall consist
of scientific and academic leaders in the field of High Risk Plaque, scientists from Participant companies and/or individuals with expertise in other selected fields indirectly related to the High Risk Plaque Field such as patient advocacy, medical
specialty, payors or the federal government. Additional members of the SPB may be nominated by the SPB or by members of the JSC. The SPB shall approve new members or remove its members by a majority vote. In addition, after approval by the SPB, new
members of the SPB employed by for-profit corporations which are not sponsors of the HRP Initiative must be approved by the JSC. The JSC shall decide the maximum number of SPB members. The JSC may remove the Co-Chairs of the SPB or dissolve the
entire SPB at any time by majority vote with or without cause. 
 (c) Meetings. The SPB shall establish a schedule of
times for regular meetings, taking into account, without limitation, the planning needs of the HRP Initiative and the responsibilities of the SPB. The Secretary shall have the responsibility for preparing and circulating to each SPB member an agenda
for each SPB meeting not later than one (1) week prior to such meeting. The SPB shall meet not less than once per calendar quarter or at such other intervals as it deems appropriate. The SPB shall give all members of the SPB proper and timely
notice of any meeting to be held. Meetings of the SPB may be held in person or by teleconference or videoconference. 
 (d)
Quorum. At each SPB meeting, (i) the presence of a majority of the SPB members shall constitute a quorum and (ii) each member who is present shall have one vote on all matters before the SPB at such meeting. All decisions of the SPB
shall be made by vote or written consent by the majority of all members. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (e) Minutes; Updates. The SPB shall keep minutes of its meetings that record all
decisions and all actions recommended or taken in reasonable detail. Drafts of the minutes of each meeting, as well as an update on the status of all Program Activities, shall be prepared and circulated to the members of the SPB and JSC by the
Secretary within a reasonable time, not to exceed ten (10) business days, after the meeting. Each member of the SPB shall have the opportunity to provide comments on the draft minutes. Draft minutes shall be approved or disapproved (and, in the
case of the latter, revised) as soon as practicable. Upon approval, final minutes of each meeting shall be circulated to the members of the SPB by the Secretary. 
  

	 	3.3	Initiative Manager. 

 (a)
Designation. As soon as practicable after the Effective Date, BGM shall recruit and supervise a person who shall oversee the day-to-day conduct of the Program Activities (the “Initiative Manager”). If requested by the SPB or JSC
Co-chairs, the Initiative Manager may attend all meetings of the JSC and the SPB, as the case may be, as a non-voting participant. 
 (b) Responsibilities. The Initiative Manager shall be responsible for (i) planning, coordinating and managing the conduct of the Program Activities; (ii) performing such tasks in support of the HRP Initiative as may be
requested by the JSC. 
 4. Reports; Access to Data and Material; Confidentiality; Publication. 
 4.1 Reports; Data. BGM shall provide the SPB with copies of all written reports (collectively, the “Reports”) that are
prepared by it in connection with the conduct of any Program Activity within four (4) months following the completion of a Program Activity or termination of the HRP Initiative. BGM shall also provide each Participant with copies of electronic
files containing the Data as soon as practicable following analysis and reporting of a Program Activity. Notwithstanding anything herein to the contrary, the parties agree that in no case will BGM share information with any Participant, with the JSC
and the SPB or any other third party that would constitute identifiable health information under Applicable Law. 
 4.2
Material. When possible, studies will be designed to provide extra materials for distribution to Participant and, if requested by such party, the other sponsors. BGM shall provide Participant with aliquots of such materials collected and/or
created during the HRP Initiative (“HRP Materials”). Participant may use the HRP Materials for research, drug discovery and development purposes without further obligation to BGM or any other sponsor of the HRP Initiative. 
 4.3 Confidentiality. Participant, BGM and the other sponsors shall not disclose any Confidential Information received in connection
with this Agreement, or the contents of any Reports (including without limitation, any Data) to any third party except for its Affiliates and its collaborators or advisors that are bound by terms of confidentiality no less strict than those set
forth herein, during the term of this Agreement and for a period of ten (10) years after the date of expiration or termination of this Agreement without the prior written consent of, during the term of this Agreement, the JSC, and after the
term of this Agreement, a majority of BGM, Participant and the other sponsors of the HRP Initiative. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 This Agreement shall not restrict Participant, BGM or any other sponsor from complying with a lawfully
issued governmental order or legal requirement, including the obligation to report adverse drug experiences to competent regulatory authorities, to produce or disclose Confidential Information; provided, however, that Participant, BGM or any other
sponsor, as applicable, shall promptly notify the party having disclosed Confidential Information to enable such party to oppose the order or obtain a protective order and Participant, BGM or any other sponsor, as applicable, shall cooperate fully
with the disclosing party in any such proceeding. 
 4.4 Publication. All publications or public presentations of the
Data shall be prepared or approved by the SPB, subjected to peer review in accord with prevailing scientific custom. The SPB shall provide the JSC with copies of any such publication or public presentation thirty (30) days prior to publication
or public release. 
 5. IP Ownership; License Grants. 
 5.1 Ownership; Patent Filings. Subject to the rights granted to Participant and the other sponsors hereunder, all Project Inventions
and Data shall be owned by BGM. BGM shall (a) provide the JSC with copies of all patent applications to be filed hereunder for Project Inventions in sufficient time to allow for review and comment by the JSC; (b) consult with the JSC
regarding the filing and contents of any such application; and (c) take into consideration in good faith the advice and suggestions of the JSC in connection with such filing. Following expiration of the term of this Agreement what is stated
regarding the JSC in this Section 5.1 shall instead apply to Participant and other sponsors of the HRP Initiative. In the event Participant terminates this Agreement prior to its expiration, what is stated regarding the JSC in this
Section 5.1 shall for the purpose of this Section 5.1 include Participant as well. 
 5.2 License Grant. BGM
hereby grants to Participant a non-exclusive, perpetual, royalty-free, worldwide license under all intellectual property rights that claim any Data and all inventions or discoveries made by BGM, whether alone or jointly with any third party
(a) in the performance of HRP Initiative in accordance with the HRP Program or (b) on and after the termination or expiration of this Agreement as a direct result of BGM’s use of the Data (collectively, “Project
Inventions”), for use by Participant and its Affiliates for any and all purposes in their regular course of business; provided that neither Participant, BGM or any other sponsor may sell or, except as provided in Section 5.3, sublicense
the Data and Project Inventions. 
 The JSC may negotiate and, if desirable, direct BGM to, and BGM shall, as directed by the JSC, grant
licenses to sell or sublicense the Data and Project Inventions. All proceeds of any such license shall be used in furtherance of the HRP Initiative or, after the term of this Agreement, be distributed evenly between BGM, Participant and the other
sponsors. BGM shall not grant any licenses or other intellectual property rights in or to the Project Inventions and/or Data except as explicitly set forth in this Section 5.2. 
 5.3 Use of Data. For avoidance of doubt, Participant and its Affiliates shall be permitted to further analyze the Data, to combine
the Data with its own data, and to use the Data for its internal purposes; provided, that, Participant and its Affiliates shall not publish any Data. Participant and its Affiliates may use the Data in, and in support of, patent applications being

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
submitted by or on behalf of Participant or its Affiliates. Participant shall have the right to sublicense to its Affiliates and Third Party Contractors the rights and licenses granted to it
under this Section 5.3 solely for the purpose of having any such Affiliate and/or Third Party Contractor perform services with respect to one or more Participant Proprietary Products; provided, that, it shall be a condition of any such
sublicense that such Affiliate and Third Party Contractor agrees to be bound by all of the applicable terms and conditions of this Agreement (including without limitation Section 4). If Participant grants any such sublicense to its Affiliates
and/or Third Party Contractors, Participant shall be deemed to have guaranteed that such Affiliate or Third Party Contractor will fulfill all of Participant’s obligations under this Agreement. No other rights or licenses are granted hereunder,
by implication or otherwise. Participant shall own all results, data and intellectual property developed or discovered through its use of the Data and Project Inventions without further obligation to BGM or the other sponsors of the HRP Initiative.

 6. Participation Payment. 
 6.1 Payment. Participant shall pay BGM [***] dollars [***] (US$[***]) on or before [***] (such amount, the “First Participation Payment”). Participant shall pay BGM [***] (US$[***]) on or
before [***] (such amount, the “Second Participation Payment”) (the First Participation Payment and Second Participation Payment together the “Participation Payments”). Payments shall be made in accordance with wire transfer
instructions to be provided by BGM. All payments made pursuant to this Section 6.1 shall be maintained by BGM in a dedicated account, which shall be kept separate from, and not commingled with, any other funds. 
 6.2 Use of Funds. The Participation Payments shall be used solely to perform the HRP Initiative. In the event that the Participation
Payments, when aggregated with payments received from other sponsors, are insufficient to fund the HRP Initiative as set forth in the budget included as part of a HRP Program (including as the same may be amended in accordance with this Agreement),
then the JSC shall promptly meet to devise alternative plans, such as scaling back the HRP Initiative and/or identifying one or more alternative sources of funds; provided, that, if Participant does not consent to an alternative plan or the
obtaining of such alternative funds, then this Agreement shall be subject to termination by Participant on thirty (30) days notice to BGM from the date the proposal concerned was being presented to Participant and the Participation Payments
made by such Participant shall be refunded to Participant to the extent and as provided in Section 7. 
 7. Term; Termination.

 7.1 Term. This Agreement shall commence on the Effective Date and expire on the first to occur of: (i) the
completion of the HRP Initiative and (ii) the fifth anniversary of the Effective Date. 
 7.2 Termination. This
Agreement is subject to early termination by Participant (i) as provided in Section 6.2; or (ii) at its discretion at any time following twelve (12) months of the Effective Date by giving thirty (30) days written notice. The
JSC may terminate this Agreement and the HRP Initiative by majority vote for any or no reason. Termination by the JSC will become effective immediately after approval by the committee. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 7.3 Effect of Termination; Survival. Upon any termination of this Agreement, any
portion of the Participation Payments made by a Participant which has not been spent in performance of the HRP Initiative, after deducting amounts committed for non-cancellable commitments, shall be promptly refunded by BGM to Participant. The
rights and obligations of the Parties set forth in Sections 1, 4, 5, 7 and 8 shall survive the termination or expiration of this Agreement; provided, however, that notwithstanding Section 5.2, in case Participant terminates the Agreement in
accordance with Section 7.2 (ii) the rights of the Participant set forth in Sections 1, 4, 5, 7 terminate upon the effective date of the termination. 
 8. Miscellaneous. 
 8.1 Each Party represents and warrants that it
has complied with, and is and will remain in material compliance with, all Applicable Laws, including, without limitation, the federal Food, Drug, and Cosmetic Act, as amended and regulations promulgated thereunder, and all U.S. Food and Drug
Administration (“FDA”) or foreign equivalent regulations governing, among other things, the protection of human subjects and regulations governing clinical investigators in its performance under this Agreement. BGM represents and
warrants that, in any of its provisions of Data, Project Inventions, and HRP Materials, it does not and will not infringe the rights of any third party, including without limitation, intellectual property and privacy rights or violate any Applicable
Law. Without limiting the foregoing sentence, if either Party becomes aware of any third party intellectual property rights that may relate to such provision of Data, Project Inventions and HRP Materials, it shall so notify the other Party, and the
Parties shall confer in good faith to avoid potential infringement of such third party intellectual property rights. 
 8.2
NO WARRANTIES. EXCEPT AS SPECIFICALLY STATED HEREIN, THE PARTIES MAKE NO EXPRESS OR IMPLIED WARRANTY AS TO ANY MATTER WHATSOEVER, INCLUDING THE CONDITIONS OF THE RESEARCH OR ANY INVENTION, MATERIAL, OR DATA, WHETHER TANGIBLE OR INTANGIBLE,
MADE OR DEVELOPED UNDER OR OUTSIDE THE SCOPE OF THIS AGREEMENT OR THE OWNERSHIP, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF ANY INVENTION, DATA OR MATERIAL, OR THAT A TECHNOLOGY UTILIZED BY A PARTY IN THE PERFORMANCE OF THE HRP PROGRAM
DOES NOT INFRINGE ANY THIRD-PARTY PATENT RIGHTS. 
  

	 	8.3	Indemnification and Liability. 

 (a) Subject to Section 8.3(c), Participant agrees to hold BGM and its respective officers, directors, employees and agents (each, “BGM Indemnitee”), harmless and to indemnify each BGM Indemnitee for all liabilities, demands,
damages, expenses and losses claimed by a third party (“Losses”) arising out of the use by Participant of the Data and/or the Project Inventions, for any purpose; provided, however, that such indemnification shall not be provided to any
BGM Indemnitee for Losses to the extent such Losses arises out of: (i) a breach of this Agreement, including without limitation, the representations and warranties of Section 8.1, by any BGM Indemnitee, (ii) a deviation from the HRP
Program by any BGM Indemnitee, or (iii) the negligence, recklessness, or willful misconduct of any BGM Indemnitee. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (b) Subject to Section 8.3(c), BGM agrees to hold Participant and its respective
officers, directors, employees and agents (each a “Participant Indemnitee”; collectively with BGM Indemnitee, “Indemnitee”), harmless and to indemnify each Participant Indemnitee for all Losses arising out of a breach of this
Agreement, including without limitation, the representations and warranties of Section 8.1, by BGM; provided, however, that such indemnification shall not be provided to Participant Indemnitee for a Losses to the extent such Losses arises out
(i) a breach of this Agreement, including without limitation, the representations and warranties of Section 8.1, by any Participant Indemnitee, (ii) a deviation from the HRP Program by any Participant Indemnitee, or (iii) the
negligence, recklessness, or willful misconduct of any Participant Indemnitee. 
 (c) Each Indemnitee shall give the
indemnifying Party prompt written notice of any claim of Losses. In no event shall the indemnifying Party be liable for any Losses to the extent such Losses result from any delay in providing such notice. Regardless of whether the indemnifying Party
chooses to defend or prosecute any third party claim for Losses, the Indemnitee shall, and shall use commercially reasonable efforts to cause each other Indemnitee to, cooperate in the defense or prosecution thereof and shall furnish such records,
information and testimony, provide such assistance as may be reasonably requested in connection therewith. The indemnifying Party shall reimburse the Indemnitee for all its reasonable out-of-pocket expenses in connection therewith. 
 (c) At its option, the indemnifying Party may assume the defence of any claim by a third party for which indemnity is sought by an
Indemnitee hereunder, by giving written notice to the Indemnitee. 
 (d) No Indemnitee shall admit any liability with respect
to, or settle, compromise or discharge, any claim by a third party for which indemnity is sought by an Indemnitee hereunder without the prior written consent of the indemnifying Party. 
 8.4 Governing Law. The construction, validity, performance and effect of this Agreement will be governed by the laws of the State of
New York without regard to provisions relating to conflicts of laws. Any dispute arising out of or relating to this Agreement shall be addressed amicably in accordance with Section 3.1(f). In the event a resolution to the dispute cannot be
obtained, the dispute shall be resolved through arbitration before a neutral. The Parties shall select a mutually acceptable independent, impartial and conflicts-free neutral to preside over the proceeding. If the Parties are unable to agree on a
mutually acceptable neutral, each Party will select one independent, impartial and conflicts-free neutral and those two neutrals will select a third independent, impartial and conflicts-free neutral. None of the neutrals selected may be current or
former employees, officers or directors of either Party, its subsidiaries or Affiliates. No discovery shall be permitted by any means, including depositions, interrogatories, requests for admissions, or production of documents. Such arbitration
shall take place in New York City, NY and, subject to the terms and conditions of this Section 8.4, shall proceed in accordance with the commercial arbitration rules of the American Arbitration Association (“AAA”) and the laws of the
state of New York without regard to the provisions thereof concerning conflict of laws. 
 8.5 Waivers. None of the
provisions of this Agreement will be considered waived by any Party unless a waiver is given in writing to the other Party. The failure of a Party to insist upon strict performance of any of the terms and conditions hereof, or failure or delay to
exercise any rights provided herein or by law, will not be deemed a waiver of any rights of any Party. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 8.6 Amendments. This Agreement shall only be amended by a written amendment signed by
BGM and Participant. 
 8.7 Assignment. Neither this Agreement nor any rights or obligations of any Party hereunder will
be assigned or otherwise transferred by either Party without the prior written consent of the other Party. 
 8.8
Notices. All notices pertaining to or required by this Agreement will be in writing, signed by an authorized representative of the notifying Party, and delivered by first class, registered, or certified mail, or by an express/overnight
commercial delivery service, prepaid and properly addressed to the other party at the address set forth above, or to any other address designated in writing by the other Party. Notices to BGM shall be directed to “President”; notices to
Participant shall be directed to James C. Stolzenbach, Divisional Vice President Heart Failure and Dyslipidemia, Dept R449, Bldg. AP34-1N, Abbott Park Road, Abbott Park, IL 60064-6194. Notices will be considered timely if received on or before the
established deadline date or sent on or before the deadline date as verifiable by U.S. Postal Service postmark or dated receipt from a commercial carrier. Any Party may change its address by notice given to the other Party in the manner set forth
above. 
 8.9 Use of Name; Press Releases. Participant shall not issue any press releases, or make other public
statements, that include reference or rely upon the Data or the HRP Program without the prior written consent of the JSC. The JSC shall approve and issue all press releases related to the HRP Initiative. Notwithstanding the foregoing, BGM and
Participant shall each have the right to publicize Participant’s support of the HRP Initiative. 
 IN WITNESS WHEREOF, the
undersigned have executed this Agreement as of the Effective Date. 
  

			
	BG MEDICINE, INC.
		
	By:	 	 /s/ Pieter Muntendam, MD

	Name:	 	Pieter Muntendam, MD
	Title:	 	President and CEO

  

			
	ABBOTT LABORATORIES
		
	By:	 	 /s/ John M. Leonard, MD

	Name:	 	John M. Leonard, MD
	Title:	 	 Senior Vice President
 Pharmaceuticals, Research & Development

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit A-1 
 HRP Program — Version 2.5 
 Background 
 The HRP Program is a pre-competitive multi-year program that encompasses original research and other activities to support the development of a novel
clinical paradigm for high-risk plaque. 
 The program is governed by a Joint Steering Committee (JSC) and Scientific Program Board as outlined
in the Participation Agreement. 
 The JSC is responsible for the development of the initial HRP Program and its subsequent expansions and
modifications. 
 The following studies are in various stages of design, planning or execution as authorized by the JSC. 
 Current Program Outline 
  

			
	Title:	  	Biomarker Discovery of High-Risk Patient
	Partner:	  	Duke University Medical School, NC, USA
	Objective:	  	Identification of biomarkers that correspond to an increased risk for coronary events
	Design:	  	Case-control study using specimen from CATHGEN biobank
	Start:	  	Jan 2007 (completed)
		
	Title:	  	Systems Biology of Human Carotid Plaque
	Partner:	  	CARIM — Univ. of Maastricht, The Netherlands
	Objective:	  	Identification of plaque biomarkers of human plaque
	Design:	  	Comparative systems analysis involving two high-risk plaque types
	Start:	  	Nov 2006 (feasibility - completed); Nov 2007 (main study - ongoing)
		
	Title:	  	BioImage Study
	Partner:	  	Humana, Univ. of Miami
	Objective:	  	Identification of plasma and imaging biomarkers with superior characteristics than Framingham Risk Score
	Design:	  	Prospective outcomes study in at-risk volunteers recruited from health insurance plan with monitoring of three-year event-rates
	Start:	  	Jan 2008 (ongoing)
		
	Title:	  	Copenhagen Heart Study — Plasma Biomarker Discovery of Risk for First MI(*)
	Partner:	  	Copenhagen General Population Study
	Objective:	  	Identification of plasma biomarkers risk of first MI over subsequent 2-3 years
	Design:	  	Case-control Study involving Copenhagen Heart Study samples
	Start:	  	Q1 2008 (ongoing)

  

 A-1 
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule
406 of the Securities Act of 1933, as amended. 

			
	Title:	  	Framingham Biomarker Consortium (*)
	Partner:	  	Framingham Heart Study, NHLBI
	Objective:	  	Identification of metabolomic markers on Framingham Heart Study samples plasma and access to Framingham data for HRP Participant Companies
	Design:	  	Retrospective study of Framingham samples and imaging studies
	Start:	  	Q2 2008 (planning)
		
	Title:	  	Regulatory Framework
	Partner:	  	Covington & Burling, DC, USA
	Objective:	  	Define a regulatory framework for diagnostic and therapeutic products for high-risk plaque
	Design:	  	n.a.
	Start:	  	October 2006 (ongoing)

  

 A-2 
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule
406 of the Securities Act of 1933, as amended.Participation Agreement

 Exhibit 10.12 
 Participation Agreement 
 This Participation Agreement
(this “Agreement”) is entered into as of the 31st day of March, 2008 (the “Effective Date”) by and between BG Medicine, Inc., a corporation having offices at 610 N. Lincoln Street, Waltham, Massachusetts 02451 (“BGM”)
and Takeda Pharmaceutical Company Limited, 1-1, Doshomachi 4-Chome, Chuo-ku, Osaka 540- 8645, Japan (“Participant”; each of Participant and BGM are sometimes referred to individually as a “Party” and collectively as the
“Parties”). 
 WHEREAS, BGM and leading healthcare companies, including Merck, AstraZeneca and Philips, intend to
collectively design and conduct a number of activities (the “HRP Initiative”) in order to advance the understanding, recognition and management of High Risk Plaque for the benefit of all stakeholders in the healthcare system as described
in the form of Program Outline to be attached hereto as Exhibit A-1 (the “HRP Program, as further defined below”); and 
 WHEREAS, BGM will administer, coordinate and implement the HRP Program; and 
 WHEREAS, Participant desires to sponsor the HRP Initiative and to obtain access to the Data (as defined below) generated in the performance of the HRP Initiative, and a non-exclusive license under certain intellectual property rights, as
set forth herein. 
 NOW, THEREFORE, in consideration of the foregoing, and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows. 
 1.
Definitions. Capitalized terms used herein shall have the definition provided in the introductory paragraph or recitals above, or the definition provided below, as applicable. 
 “Affiliate” means any corporation, firm, partnership or other entity which directly or indirectly controls or is controlled
by or is under common control with a Party. For purposes of this definition, “control” means ownership, directly or through one or more Affiliates, of (a) fifty percent (50%) or more of the shares of stock entitled to vote for
the election of directors, in the case of a corporation, (b) fifty percent (50%) or more of the equity interests in the case of any other type of legal entity, status as a general partner in any partnership, or (c) any other
arrangement whereby a Party controls or has the right to control the Board of Directors or equivalent governing body of a corporation or other entity. 
 “Applicable Law” means all applicable common law, laws, constitutional provisions, ordinances, statutes, rules, regulations, administrative rulings, executive orders and other
pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision, agency or other body, domestic or foreign, including but not limited to any applicable rules,
regulations, guidelines, or other requirements of governmental agencies that may be in effect from time to time. 

 “Confidential Information” means confidential scientific, business, or
financial information provided by one Party or other sponsor of the HRP Initiative (a “disclosing Party”) to any other Party or other sponsor of the HRP Initiative (a “receiving Party”) pursuant to this Agreement; provided, that,
Confidential Information does not include: 
  

	(a)	information that is or becomes publicly known or that is or becomes available from public sources; 

  

	(b)	information that is already known by the receiving Party, or information that is independently created or compiled by the receiving Party without reference to or use of
the provided information; or 

  

	(c)	information that relates to potential hazards or cautionary warnings associated with the production, handling, or use of the subject matter of the HRP Program; or

  

	(d)	information that is provided to the receiving Party by a third party who is not bound by obligations of confidentiality to the disclosing Party.

 “Data” means all data first produced in the performance of the HRP Initiative as described in
the HRP Program that has been anonymized so as to be outside the scope of international data protection laws generally, as well as, deidentified in accordance with the requirements of the Health Insurance Portability and Accountability Act (HIPAA)
Privacy Rule, the regulations promulgated thereunder and Applicable Law. 
 “Participant Proprietary Product”
means any drug compound or medical device controlled by Participant. For purposes of this definition, “control” means the possession by Participant of (a) a 50% or more ownership interest in a drug compound or medical device or
(b) a licensing interest that permits Participant to exclusively develop, manufacture and sell such drug compound or medical device in some or all indications, uses and countries. 
 “Project Invention” shall have the definition provided in Section 5.2. 
 “Reports” shall have the definition provided in Section 4. 
 “HRP Program” means a written plan describing the activities to be carried out in support of the HRP Initiative; as such
written plan may be amended, modified or updated. Each HRP Program shall include the resource requirements of, and budget applicable to, the conduct of each HRP Program. The initial HRP Program shall be developed by the SPB and approved by the JSC
prior to sixty (60) days after the Effective Date and attached hereto as Exhibit A-l and each additional HRP Program shall be developed by the SPB and approved by the JSC prior to the initiation of any Program Activities with respect to
each such HRP Program and attached hereto as addendums to Exhibit A. 
 “Program Activity” means the
activities conducted as part of the HRP Initiative as described in the applicable HRP Program. 

 “Scientific Program Board” or “SPB” means the scientific advisory
board comprised of academic experts in applicable fields, representatives of BGM, Participant, and other sponsors of the HRP Initiative that are approved by the JSC, as further described in Section 3.2. 
 “Joint Steering Committee” or the “JSC” means the joint steering committee comprised of those representatives of
BGM, Participant, and other sponsors of the HRP Initiative, as further described in Section 3.1. 
 “Third Party
Contractor” means any third party contract research organization, research laboratory or similar entity engaged by Participant to perform development services with respect to any Participant Proprietary Product. 
 2. HRP Initiative. 
 2.1 Performance of HRP Initiative. BGM shall coordinate, administer and execute the HRP Initiative as provided in the HRP Program. The HRP Initiative shall be implemented through the conduct by BGM of Program Activities, each of
which will be described in the HRP Program and/or in amendments thereto. 
 2.2 HRP Program; Amendments. Within sixty
(60) days of the Effective Date the initial HRP Program shall be prepared by the SPB, approved by the JSC and attached hereto as Exhibit A-1. Any changes to the HRP Program shall be prepared by the SPB and approved by the JSC in
accordance with Section 3.1 below. 
 2.3 Additional Participants. Excluding BGM, the HRP Initiative shall have no
less than two (2) sponsors (including Participant). BGM will actively recruit additional participants (“Subsequent Participants”) until a total of five ( 5 ) Participants have executed participation agreements. To join the HRP
Initiative, Subsequent Participants shall execute participation agreements including the same terms set forth in this Agreement. Subsequent Participants must execute participation agreements joining the HRP Initiative prior to 12/31/2007;
Thereafter, Subsequent Participants shall only be permitted to join the HRP Initiative with the consent of at least two-thirds of the JSC. Any terms of a Subsequent Participant’s agreement materially different from this Agreement shall be
approved in writing by the JSC, in addition to any approval process by which BGM is obligated, such approval not to be unreasonably withheld. 
 2.4 Open Technology. In order to promote widespread availability and adoption of imaging technology inventions arising from the HRP Initiative that are specific to imaging technology equipment, and
their applications to various types of imaging equipment, these imaging technology equipment inventions and applications resulting from use of the Project Inventions shall be made available under customary multi-vendor terms and polices to GE,
Philips, and Siemens and any other established manufacturer of proprietary imaging equipment who possesses the appropriate level of know-how and experience to implement new technology arising from the HRP Initiative. 

 3. Governance 
 3.1. Joint Steering Committee. 
 (a) Formation; Responsibilities. As
soon as practicable after the Effective Date, the Joint Steering Committee shall be formed to (i) oversee the overall conduct and progress of the HRP Initiative; (ii) establish such additional committees as may be necessary to achieve the
objectives of the HRP Initiative and, to the extent so established, approve the governing procedures applicable thereto; (iii) finalize and approve each Program Activity (including all budgets and work plans included therein) and/or each
amendment to any HRP Program proposed by the SPB; (iv) make all decisions with respect to the initiation and performance of any Program Activity and the application of funds to such Program Activity; (v) approve all press releases related
to the HRP Initiative; (vi) review and approve all patent filings to be made covering any Project Inventions; (vii) provide a forum for the resolution of disputes among the Parties with respect to the HRP Initiative; (viii) negotiate,
and if desirable, grant commercialization rights to the Data and Project Inventions; (ix) if necessary, dissolve the SPB; and (x) approve, and if necessary, replace or discharge the Co-Chairs of the SPB. 
 (b) Designation of Representatives. BGM and each Participant shall have the right to designate one (1) member to serve on the
JSC. Participant shall provide written notice to BGM of the name of such member promptly after the Effective Date. Unless otherwise agreed by the Parties, (i) the Co-chairs of the SPB shall be non-voting members of the JSC; (ii) the
representative of BGM on the JSC shall be the Chairs of the JSC and (iii) the representative of BGM on the JSC shall serve as Secretary to the JSC. Each Party shall have the right at any time to substitute individuals, on a permanent or
temporary basis, for any of its previously designated representatives to the JSC by giving written notice to the other Party. 
 (c) Meetings. The JSC shall establish a schedule of times for regular meetings, taking into account, without limitation, the planning needs of the HRP Initiative and the responsibilities of the JSC. The Secretary shall have the
responsibility for preparing and circulating to each JSC member an agenda for each JSC meeting not later than one (1) week prior to such meeting. The JSC shall meet not less than once per calendar quarter or at such other intervals as it deems
appropriate. The Secretary shall give all members of the JSC proper and timely notice of any meeting to be held. Meetings of the JSC may be held in person or by teleconference or videoconference. Upon prior request by any member of the JSC, any JSC
meeting may be conducted excluding the Co-chairs of the SPB. 
 (d) Quorum. At each JSC meeting, (i) the presence of
at least a majority of the JSC members shall constitute a quorum and (ii) each member who is present shall have one vote on all matters before the JSC at such meeting. All decisions of the JSC shall be made by vote or written consent of the
majority of all members. In the event that the JSC is unable to resolve any matter before it for consideration, such matter shall be resolved in accordance with Section 3.l(f). 
 (e) Minutes; Updates. The JSC shall keep minutes of its meetings that record all decisions and all actions recommended or taken in
reasonable detail. Drafts of

 
the minutes of each meeting, as well as an update on the status of all Program Activities, shall be prepared and circulated to the members of the JSC by the Secretary within a reasonable time,
not to exceed ten (10) business days, after the meeting. Each member of the JSC shall have the opportunity to provide comments on the draft minutes. Draft minutes shall be approved or disapproved (and, in case of the latter, revised) as soon as
practicable. Upon approval, final minutes of each meeting shall be circulated to the members of the JSC by the Secretary. 
 (f)
Dispute Resolution. The JSC members shall use reasonable efforts to reach agreement on any and all matters presented to it. In the event that, despite such reasonable efforts, the agreement on a particular matter cannot be reached by the JSC
in accordance with Section 3.l(d) within ten (10) days after the JSC first meets to consider such matter (each such matter, a “Disputed Matter”), then the JSC shall abandon consideration of the Disputed Matter and the subject
matter of the Disputed Matter shall not be implemented. 
 3.2 Scientific Program Board. 
 (a) Formation; Responsibilities. As soon as practicable after the Effective Date, the Scientific Program Board shall be formed to
(i) provide advice on the direction and performance of the Program Activities that make up the HRP Initiative; (ii) propose and design Program Activities for submission to and the approval of the JSC; (iii) propose such additional
scientific subcommittees as may be necessary to achieve the objectives of any Program Activity for submission to and the approval of the JSC; (iv) identify any public disclosure needs related to the HRP Initiative and develop scientific
disclosure and publication materials for approval by the JSC; and (v) review and present to the JSC all Project Inventions. The SPB shall use reasonable efforts to reach agreement on any and all matters; provided, that, in the event that the
SPB is unable to resolve any matter before it, such matter shall be referred to the JSC for resolution. BGM shall give good faith consideration to the advice of the SPB with respect to the conduct of all Program Activities; provided, that BGM shall
at all times adhere to the requirements of the HRP Program in the performance of the HRP Initiative. 
 (b) Designation of
Representatives. The JSC shall appoint the Co-Chairs and Secretary of the SPB, which shall consist of scientific and academic leaders in the field of High Risk Plaque, scientists from Participant companies and/or individuals with expertise in
other selected fields indirectly related to the High Risk Plaque Field such as patient advocacy, medical specialty, payors or the federal government. Additional members of the SPB may be nominated by the SPB or by members of the JSC. The SPB shall
approve new members or remove its members by a majority vote. In addition, after approval by the SPB, new members of the SPB employed by for-profit corporations which are not sponsors of the HRP Initiative must be approved by the JSC. The JSC shall
decide the maximum number of SPB members. The JSC may remove the Co-Chairs of the SPB or dissolve the entire SPB at any time by majority vote with or without cause. 
 (c) Meetings. The SPB shall establish a schedule of times for regular meetings, taking into account, without limitation, the planning needs of the HRP

 
Initiative and the responsibilities of the SPB. The Secretary shall have the responsibility for preparing and circulating to each SPB member an agenda for each SPB meeting not later than one
(1) week prior to such meeting. The SPB shall meet not less than once per calendar quarter or at such other intervals as it deems appropriate. The SPB shall give all members of the SPB proper and timely notice of any meeting to be held.
Meetings of the SPB may be held in person or by teleconference or videoconference. 
 (d) Quorum. At each SPB meeting,
(i) the presence of a majority of the SPB members shall constitute a quorum and (ii) each member who is present shall have one vote on all matters before the SPB at such meeting. All decisions of the SPB shall be made by vote or written
consent by the majority of all members. 
 (e) Minutes; Updates. The SPB shall keep minutes of its meetings that record
all decisions and all actions recommended or taken in reasonable detail. Drafts of the minutes of each meeting, as well as an update on the status of all Program Activities, shall be prepared and circulated to the members of the SPB and JSC by the
Secretary within a reasonable time, not to exceed ten (10) business days, after the meeting. Each member of the SPB shall have the opportunity to provide comments on the draft minutes. Draft minutes shall be approved or disapproved (and, in the
case of the latter, revised) as soon as practicable. Upon approval, final minutes of each meeting shall be circulated to the members of the SPB by the Secretary. 
 3.3 Initiative Manager. 
 (a) Designation. As soon as practicable
after the Effective Date, BGM shall recruit and supervise a person who shall oversee the day-to-day conduct of the Program Activities (the “Initiative Manager”). If requested by the SPB or JSC Co-chairs, the Initiative Manager may attend
all meetings of the JSC and the SPB, as the case may be, as a non-voting participant. 
 (b) Responsibilities. The
Initiative Manager shall be responsible for (i) planning, coordinating and managing the conduct of the Program Activities; (ii) performing such tasks in support of the HRP Initiative as may be requested by the JSC. 
 4. Reports; Access to Data and Material; Confidentiality; Publication. 
 4.1 Reports; Data. BGM shall provide the SPB with copies of all written reports (collectively, the “Reports”) that are
prepared by it in connection with the conduct of any Program Activity within four (4) months following the completion of a Program Activity or termination of the HRP Initiative. BGM shall also provide each Participant with copies of electronic
files containing the Data as soon as practicable following analysis and reporting of a Program Activity. Notwithstanding anything herein to the contrary, the parties agree that in no case will BGM share information with any Participant, with the JSC
and the SPB or any other third party that would constitute identifiable health information under Applicable Law. 
 4.2
Material. When possible, studies will be designed to provide extra materials for distribution to Participant and, if requested by such party, the other sponsors. BGM

 
shall provide Participant with aliquots of such materials collected and/or created during the HRP Initiative (“HRP Materials”). Participant may use the HRP Materials for research, drug
discovery and development purposes without further obligation to BGM or any other sponsor of the HRP Initiative. 
 4.3
Confidentiality. Participant, BGM and the other sponsors shall not disclose any Confidential Information received in connection with this Agreement, or the contents of any Reports (including without limitation, any Data) to any third party
except for its Affiliates and its collaborators or advisors that are bound by terms of confidentiality no less strict than those set forth herein, during the term of this Agreement and for a period of ten (10) years after the date of expiration
or termination of this Agreement without the prior written consent of, during the term of this Agreement, the JSC, and after the term of this Agreement, a majority of BGM, Participant and the other sponsors of the HRP Initiative. 
 This Agreement shall not restrict Participant, BGM or any other sponsor from complying with a lawfully issued governmental order or legal requirement,
including the obligation to report adverse drug experiences to competent regulatory authorities, to produce or disclose Confidential Information; provided, however, that Participant, BGM or any other sponsor, as applicable, shall promptly notify the
party having disclosed Confidential Information to enable such party to oppose the order or obtain a protective order and Participant, BGM or any other sponsor, as applicable, shall cooperate fully with the disclosing party in any such proceeding.

 4.4 Publication. All publications or public presentations of the Data shall be prepared or approved by the SPB,
subjected to peer review in accord with prevailing scientific custom. The SPB shall provide the JSC with copies of any such publication or public presentation thirty (30) days prior to publication or public release. 
 5. IP Ownership; License Grants. 
 5.1 Ownership; Patent Filings. Subject to the rights granted to Participant and the other sponsors hereunder, all Project Inventions and Data shall be owned by BGM. BGM shall (a) provide the
JSC with copies of all patent applications to be filed hereunder for Project Inventions in sufficient time to allow for review and comment by the JSC; (b) consult with the JSC regarding the filing and contents of any such application; and
(c) take into consideration in good faith the advice and suggestions of the JSC in connection with such filing. Following expiration of the term of this Agreement what is stated regarding the JSC in this Section 5.1 shall instead apply to
Participant and other sponsors of the HRP Initiative. In the event Participant terminates this Agreement prior to its expiration, what is stated regarding the JSC in this Section 5.1 shall for the purpose of this Section 5.1 include
Participant as well. 
 5.2 License Grant. BGM hereby grants to Participant a non-exclusive, perpetual, royalty-free,
worldwide license under all intellectual property rights that claim any Data and all inventions or discoveries made by BGM, whether alone or jointly with any third party (a) in the performance of HRP Initiative in accordance with the HRP
Program or

 
(b) on and after the termination or expiration of this Agreement as a direct result of BGM’s use of the Data (collectively, “Project Inventions”), for use by Participant and its
Affiliates for any and all purposes in their regular course of business; provided that neither Participant, BGM or any other sponsor may sell or, except as provided in Section 5.3, sublicense the Data and Project Inventions. 
 The JSC may negotiate and, if desirable, direct BGM to, and BGM shall, as directed by the JSC, grant licenses to sell or sublicense the Data and Project
Inventions. All proceeds of any such license shall be used in furtherance of the HRP Initiative or, after the term of this Agreement, be distributed evenly between BGM, Participant and the other sponsors. BGM shall not grant any licenses or other
intellectual property rights in or to the Project Inventions and/or Data except as explicitly set forth in this Section 5.2. 
 5.3 Use of Data. For avoidance of doubt, Participant and its Affiliates shall be permitted to further analyze the Data, to combine the Data with its own data, and to use the Data for its internal purposes; provided, that, Participant
and its Affiliates shall not publish any Data. Participant and its Affiliates may use the Data in, and in support of, patent applications being submitted by or on behalf of Participant or its Affiliates. Participant shall have the right to
sublicense to its Affiliates and Third Party Contractors the rights and licenses granted to it under this Section 5.3 solely for the purpose of having any such Affiliate and/or Third Party Contractor perform services with respect to one or more
Participant Proprietary Products; provided, that, it shall be a condition of any such sublicense that such Affiliate and Third Party Contractor agrees to be bound by all of the applicable terms and conditions of this Agreement (including without
limitation Section 4). If Participant grants any such sublicense to its Affiliates and/or Third Party Contractors, Participant shall be deemed to have guaranteed that such Affiliate or Third Party Contractor will fulfill all of
Participant’s obligations under this Agreement. No other rights or licenses are granted hereunder, by implication or otherwise. Participant shall own all results, data and intellectual property developed or discovered through its use of the
Data and Project Inventions without further obligation to BGM or the other sponsors of the HRP Initiative. 
 6. Participation
Payment. 
 6.1 Payment. Participant shall pay BGM five million dollars (US$5,000,000) within forty (40) days
after the Effective Date (such amount, the “Participation Payment”). Payment shall be made in accordance with wire transfer instructions to be provided by BGM. All payment made pursuant to this Section 6.1 shall be maintained by BGM
in a dedicated account, which shall be kept separate from, and not commingled with, any other funds. 
 6.2 Use of Funds.
The Participation Payment shall be used solely to perform the HRP Initiative. In the event that the Participation Payment, when aggregated with payments received from other sponsors, are insufficient to fund the HRP Initiative as set forth in the
budget included as part of a HRP Program (including as the same may be amended in accordance with this Agreement), then the JSC shall promptly meet to devise alternative plans, such as scaling back the HRP Initiative and/or identifying one or more

 
alternative sources of funds; provided, that, if Participant does not consent to an alternative plan or the obtaining of such alternative funds, then this Agreement shall be subject to
termination by Participant on thirty (30) days notice to BGM from the date the proposal concerned was being presented to Participant and the Participation Payment made by such Participant shall be refunded to Participant to the extent and as
provided in Section 7. 
 7. Term; Termination. 
 7.1 Term. This Agreement shall commence on the Effective Date and expire on the first to occur of: (i) the completion of the HRP Initiative and (ii) the fifth anniversary of the Effective
Date. 
 7.2 Termination. This Agreement is subject to early termination by Participant (i) as provided in
Section 6.2; (ii) at its discretion at any time following twelve (12) months of the Effective Date by giving thirty (30) days written notice or (iii) as provided in Section 7.2.1. The JSC may terminate this Agreement
and the HRP Initiative by majority vote for any or no reason. Termination by the JSC will become effective immediately after approval by the committee. 
 7.2.1 Either Participant or BGM may terminate this Agreement by written notice with immediate effect if the other Party ceases to carry on business as a going concern, becomes the object of voluntary or
involuntary proceedings in bankruptcy or liquidation or a receiver is appointed with respect to a substantial part of its assets. If this Agreement is so terminated, Sections 1, 4, 5, 7 and 8 shall survive. All other provisions of this Agreement
shall terminate and be of no further effect. Notwithstanding the foregoing, in case of termination by Participant or BCG pursuant to section 7.2.1, this Agreement shall constitute an executory contract under Section 365 of the United States
Bankruptcy Code, 1 l U.S.C. § 101 et seq. (hereinafter referred to as the “Bankruptcy Code”). All rights and licenses granted pursuant to this Agreement are, and shall deemed to be, licenses of and rights to “intellectual
property” as that term is defined in Section 101(35A), and used in Section 365, of the Bankruptcy Code. The Parties agree that (i) Participant, as licensee under this Agreement, shall posses and may fully exercise all of its
rights, remedies and elections afforded by and under the Bankruptcy code, and (ii) BGM, as licensor under this Agreement, shall posses and may fully exercise all of its rights, remedies and elections afforded and under the Bankruptcy Code. The
Parties further agree that in the event of the commencement of a bankruptcy case by or against BGM under the Bankruptcy Code, Participant shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual
property as that term is defined in Section 101(35A), and all embodiments of such intellectual property shall be delivered to Participant upon written request therefore by Participant so that Participant may continue to use Project Inventions
for any and all purposes in its regular course of business. 
 7.3 Effect of Termination; Survival. Upon any termination
of this Agreement, any portion of the Participation Payment made by a Participant which has not been spent in performance of the HRP Initiative, after deducting amounts committed for non-cancellable commitments, shall be promptly refunded by BGM to
Participant. The rights

 
and obligations of the Parties set forth in Sections 1, 4, 5, 7 and 8 shall survive the termination or expiration of this Agreement; provided, however, that notwithstanding Section 5.2, in
case Participant terminates the Agreement in accordance with Section 7.2 (ii) the rights of the Participant set forth in Sections 1, 4, 5, 7 terminate upon the effective date of the termination. 
 8. Miscellaneous. 
 8.1. Each Party represents and warrants that it has complied with, and is and will remain in material compliance with, all Applicable Laws, including, without limitation, the federal Food, Drug, and Cosmetic Act, as amended and regulations
promulgated thereunder, and all U.S. Food and Drug Administration (“FDA”) or foreign equivalent regulations governing, among other things, the protection of human subjects and regulations governing clinical investigators in its
performance under this Agreement. BGM represents and warrants that, in any of its provisions of Data, Project Inventions, and HRP Materials, it does not and will not infringe the rights of any third party, including without limitation, intellectual
property and privacy rights or violate any Applicable Law. Without limiting the foregoing sentence, if either Party becomes aware of any third party intellectual property rights that may relate to such provision of Data, Project Inventions and HRP
Materials, it shall so notify the other Party, and the Parties shall confer in good faith to avoid potential infringement of such third party intellectual property rights. 
 8.2 NO WARRANTIES. EXCEPT AS SPECIFICALLY STATED HEREIN, THE PARTIES MAKE NO EXPRESS OR IMPLIED WARRANTY AS TO ANY MATTER WHATSOEVER,
INCLUDING THE CONDITIONS OF THE RESEARCH OR ANY INVENTION, MATERIAL, OR DATA, WHETHER TANGIBLE OR INTANGIBLE, MADE OR DEVELOPED UNDER OR OUTSIDE THE SCOPE OF THIS AGREEMENT OR THE OWNERSHIP, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF
ANY INVENTION, DATA OR MATERIAL, OR THAT A TECHNOLOGY UTILIZED BY A PARTY IN THE PERFORMANCE OF THE HRP PROGRAM DOES NOT INFRINGE ANY THIRD-PARTY PATENT RIGHTS. 
 8.3. Indemnification and Liability. 
 (a) Subject to Section 8.3(c),
Participant agrees to hold BGM and its respective officers, directors, employees and agents (each, “BGM Indemnitee”), harmless and to indemnify each BGM Indemnitee for all liabilities, demands, damages, expenses and losses claimed by a
third party (“Losses”) arising out of the use by Participant of the Data and/or the Project Inventions, for any purpose; provided, however, that such indemnification shall not be provided to any BGM Indemnitee for Losses to the extent such
Losses arises out of: (i) a breach of this Agreement, including without limitation, the representations and warranties of Section 8.1, by any BGM Indemnitee, (ii) a deviation from the HRP Program by any BGM Indemnitee, or
(iii) the negligence, recklessness, or willful misconduct of any BGM Indemnitee. 

 (b) Subject to Section 8.3(c), BGM agrees to hold Participant and its respective
officers, directors, employees and agents (each a “Participant Indemnitee”; collectively with BGM Indemnitee, “Indemnitee”), harmless and to indemnify each BGM Indemnitee for all Losses arising out of a breach of this Agreement,
including without limitation, the representations and warranties of Section 8.1, by BGM; provided, however, that such indemnification shall not be provided to Participant Indemnitee for a Losses to the extent such Losses arises out of:
(i) a breach of this Agreement, including without limitation, the representations and warranties of Section 8.1, by any Participant Indemnitee, (ii) a deviation from the HRP Program by any Participant Indemnitee, or (iii) the
negligence, recklessness, or willful misconduct of any Participant Indemnitee. 
 (c) Each Indemnitee shall give the
indemnifying Party prompt written notice of any claim of Losses. In no event shall the indemnifying Party be liable for any Losses to the extent such Losses result from any delay in providing such notice. Regardless of whether the indemnifying Party
chooses to defend or prosecute any third party claim for Losses, the Indemnitee shall, and shall use commercially reasonable efforts to cause each other Indemnitee to, cooperate in the defense or prosecution thereof and shall furnish such records,
information and testimony, provide such assistance as may be reasonably requested in connection therewith. The indemnifying Party shall reimburse the Indemnitee for all its reasonable out-of-pocket expenses in connection therewith. 
 (d) At its option, the indemnifying Party may assume the defense of any claim by a third party for which indemnity is sought by an
Indemnitee hereunder, by giving written notice to the Indemnitee. 
 (e) No Indemnitee shall admit any liability with respect
to, or settle, compromise or discharge, any claim by a third party for which indemnity is sought by an Indemnitee hereunder without the prior written consent of the indemnifying Party. 
 8.4. Governing Law. The construction, validity, performance and effect of this Agreement will be governed by the laws of the State of
New York without regard to provisions relating to conflicts of laws. Any dispute arising out of or relating to this Agreement shall be addressed amicably in accordance with Section 3.l(f). In the event a resolution to the dispute cannot be
obtained, the dispute shall be resolved through arbitration before a neutral. The Parties shall select a mutually acceptable independent, impartial and conflicts-free neutral to preside over the proceeding. If the Parties are unable to agree on a
mutually acceptable neutral, each Party will select one independent, impartial and conflicts-free neutral and those two neutrals will select a third independent, impartial and conflicts-free neutral. None of the neutrals selected may be current or
former employees, officers or directors of either Party, its subsidiaries or Affiliates. No discovery shall be permitted by any means, including depositions, interrogatories, requests for admissions, or production of documents. Such arbitration
shall take place in New York City, NY and, subject to the terms and conditions of this Section 8.4, shall proceed in accordance with the commercial arbitration rules of the American Arbitration Association (“AAA”) and the laws of the
state of New York without regard to the provisions thereof concerning conflict of laws. 

 8.5. Waivers. None of the provisions of this Agreement will be considered waived by
any Party unless a waiver is given in writing to the other Party. The failure of a Party to insist upon strict performance of any of the terms and conditions hereof, or failure or delay to exercise any rights provided herein or by law, will not be
deemed a waiver of any rights of any Party. 
 8.6. Amendments. This Agreement shall only be amended by a written
amendment signed by BGM and Participant. 
 8.7. Assignment. Neither this Agreement nor any rights or obligations of any
Party hereunder will be assigned or otherwise transferred by either Party without the prior written consent of the other Party. 
 8.8. Notices. All notices pertaining to or required by this Agreement will be in writing, signed by an authorized representative of the notifying Party, and delivered by first class, registered, or certified mail, or by an
express/overnight commercial delivery service, prepaid and properly addressed to the other party at the address set forth above, or to any other address designated in writing by the other Party. Notices to BGM shall be directed to
“President”; notices to Participant shall be directed to Richard Urquhart, M.D., Medical Director, Strategic Development Department, Pharmaceutical Development Division, Takeda Pharmaceutical Company Limited. Notices will be considered
timely if received on or before the established deadline date or sent on or before the deadline date as verifiable by U.S. Postal Service postmark or dated receipt from a commercial carrier. Any Party may change its address by notice given to the
other Party in the manner set forth above. 
 8.9. Use of Name; Press Releases. Participant shall not issue any press
releases, or make other public statements, that include reference or rely upon the Data or the HRP Program without the prior written consent of the JSC. The JSC shall approve and issue all press releases related to the HRP Initiative.
Notwithstanding the foregoing, BGM and Participant shall each have the right to publicize Participant’s support of the HRP Initiative. 
 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the Effective Date. 
  

							
	BG MEDICINE, INC.	 	TAKEDA PHARMACEUTICAL COMPANY LIMITED
				
	By:	 	 /s/ Pieter Muntendam
	 	By:	 	 /s/ Masaomi Miyamoto

	Name:	 	Pieter Muntendam	 	Name:	 	Masaomi Miyamoto
	Title:	 	President and CEO	 	Title:	 	General Manager,
		 		 		 	Pharmaceutical Development Division

 Exhibit A-1 
 HRP Program -Version 2.5 
 Background 
 The HRP Program is a pre-competitive multi-year program that encompasses original research and other activities to support the development of a novel
clinical paradigm for high-risk plaque. 
 The program is governed by a Joint Steering Committee (JSC) and Scientific Program Board as outlined
in the Participation Agreement. 
 The JSC is responsible for the development of the initial HRP Program and its subsequent expansions and
modifications. 
 The following studies are in various stages of design, planning or execution as authorized by the JSC. 
 Current Program Outline 

			
		
	 Title:
	  	Biomarker Discovery of High-Risk Patient
	 Partner:
	  	Duke University Medical School, NC, USA
	 Objective:
	  	Identification of biomarkers that correspond to an increased risk for coronary events
	 Design:
	  	Case-control study using specimen from CATHGEN biobank
	 Start:
	  	Jan 2007 (completed)
		
	 Title:
	  	Systems Biology of Human Carotid Plaque
	 Partner:
	  	CARIM - Univ. of Maastricht, The Netherlands
	 Objective:
	  	Identification of plaque biomarkers of human plaque
	 Design:
	  	Comparative systems analysis involving two high-risk plaque types
	 Start:
	  	Nov 2006 (feasibility - completed); Nov 2007 (main study - ongoing)
		
	 Title:
	  	BioImage Study
	 Partner:
	  	Humana, Univ. of Miami
	 Objective:
	  	Identification of plasma and imaging biomarkers with superior characteristics than Framingham Risk Score
	 Design:
	  	Prospective outcomes study in at-risk volunteers recruited from health insurance plan with monitoring of three-year event-rates
	 Start:
	  	Jan 2008 (ongoing)
		
	 Title:
	  	Copenhagen Heart Study - Plasma Biomarker Discovery of Risk for First MI(*)
	 Partner:
	  	Copenhagen General Population Study
	 Objective:
	  	Identification of plasma biomarkers risk of first MI over subsequent 2-3 years
	 Design:
	  	Case-control Study involving Copenhagen Heart Study samples
	 Start:
	  	Q1 2008 (ongoing)

  

 A-1 

			
	 Title:
	  	Framingham Biomarker Consortium (*)
	 Partner:
	  	Framingham Heart Study, NHLBI
	 Objective:
	  	Identification of metabolomic markers on Framingham Heart Study samples plasma and access to Framingham data for HRP Participant Companies
	 Design:
	  	Retrospective study of Framingham samples and imaging studies
	 Start:
	  	Q2 2008 (planning)
		
	 Title:
	  	Regulatory Framework
	 Partner:
	  	Covington & Burling, DC, USA
	 Objective:
	  	Define a regulatory framework for diagnostic and therapeutic products for high-risk plaque
	 Design:
	  	n.a.
	 Start:
	  	October 2006 (ongoing)

  

 A-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]